Anika Therapeutics, Inc. (ANIK) vs Biodesix, Inc. (BDSX)
A side-by-side comparison of Anika Therapeutics, Inc. and Biodesix, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.57HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT
BDSX
Biodesix, Inc.
$29.55HealthcareDelayed quote: Oct 6, 2026, 10:08 AM EDT
Total return — ANIK vs BDSX
growth of $100 · dividends reinvested · last 6yANIK -40.8% (-8.4%/yr)BDSX -88.7% (-30.4%/yr)ANIK compounded faster over this window
Log scale — wide-divergence pair
ANIK BDSX
ANIK vs BDSX: by the numbers
- •ANIK is the larger company ($262M vs $241M market cap).
- •Both run net losses; ANIK's is the smaller (-3.14% vs -26.97% net margin).
- •BDSX grew revenue faster over the past five years (5.99% vs -2.48% CAGR).
Metrics side by side
Valuation
| Metric | ANIK | BDSX |
|---|---|---|
| Forward P/E | 18.64 | N/A |
| P/S ratio | 2.17 | 2.34 |
| P/B ratio | 1.91 | 26.30 |
| EV / EBITDA | 484.89 | N/A |
| FCF yield | 0.21% | N/A |
Profitability
| Metric | ANIK | BDSX |
|---|---|---|
| Gross margin | 62.16% | 82.50% |
| Operating margin | -4.24% | -31.37% |
| Net margin | -3.14% | -26.97% |
| ROE | -2.76% | -303.61% |
| ROIC | -3.17% | -25.73% |
Growth (annualized)
| Metric | ANIK | BDSX |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | 5.99% |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | -28.49% |
Frequently asked
- Which has grown faster, ANIK or BDSX?
- Over the past five years, BDSX grew revenue faster — ANIK at a -2.48% CAGR versus BDSX at 5.99%.
- How have ANIK and BDSX total returns compared?
- Over the past 5 years, ANIK delivered -13.40% and BDSX delivered -28.49% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.